Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494988 | 0.92 | MAOA (0.48) | CTSVCTSLMAOAMAOBALK | |
| SCHEMBL6496527 | 0.86 | CTSV (0.51) | CTSVCTSLMAOAMAOBALK | |
| SCHEMBL6498712 | 0.85 | MAOA (0.52) | CTSVCTSLMAOAMAOBCHEK1 | |
| SCHEMBL6505220 | 0.81 | CTSV (0.47) | CTSVCTSLMAOAMAOBCHEK1 | |
| SCHEMBL6499254 | 0.80 | ROCK2 (0.48) | CHEK1CA1CA2CA4CA6 | |
| SCHEMBL6505227 | 0.80 | MAOA (0.48) | CTSVCTSLMAOAMAOBCHEK1 | |
| SCHEMBL4147028 | 0.77 | TLR9 (0.49) | CTSVCTSLMAOAMAOBTRPM8 | |
| SCHEMBL6532640 | 0.75 | CTSV (0.65) | CTSVCTSLSTK10SLK | |
| SCHEMBL22541444 | 0.74 | CHEK1 (0.56) | CTSVCTSLMAOAMAOBALK | |
| SCHEMBL21185329 | 0.73 | CTSV (0.51) | CTSVCTSLMAOAMAOBTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | disclosed |
| EP-1245565-B1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
| EP-1245565-A1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | CTSV 4322/4885CTSL 3846/4885MAOA 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.